Background. Fatty acid binding protein 4 (FABP4) is mainly involved in the regulation of systemic metabolism through various lipid signaling pathways. Metabolic reprogramming is one of the important factors in the development and progression of cancer. It has been recently reported that FABP4 is closely related to the development of cancer and may be involved in tumor invasion and metastasis. Methods. In this study, we explored the expression pattern of FABP4 in pancancer through TCGA and CPTAC. Using TCGA, Kaplan-Meier Plotter, and STRING databases, to explore its diagnostic and prognostic value, and function through GO/KEGG and GSEA. Then, using the TIMER2.0 database, we investigated the correlation between FABP4 expression and immune infiltration in cancers, especially stomach adenocarcinomas (STAD) and colorectal adenocarcinoma (COADREAD). Results. Compared with normal tissues, the expression of FABP4 in more than 10 tumor tissues was lower ( ). Through the receiver operating characteristic (ROC) curve, the diagnostic value was found higher in colorectal cancer, breast cancer, thyroid cancer, and lung cancer, with the area under the curve . Through the K-M curve, FABP4 was found to correlate to the prognosis of various cancers. The results of gastric cancer and colorectal cancer are consistent. The low-expression group has a better prognosis than the high-expression group, and the expression of FABP4 in the early T and N stages of gastrointestinal tumors is lower. FABP4 highly expressed gene set is mostly enriched in extracellular matrix degradation and cell adhesion functions. Gastrointestinal tumors with high expression of FABP4 may have more immunosuppressive effects on macrophages and have a worse prognosis. Conclusion. FABP4 can be used as a diagnostic and prognostic biomarker in pancancer, and its high expression in gastrointestinal tumors suggests poor prognosis. This may be correlated to the immune infiltration of macrophages and epithelial-mesenchymal transition.
Background: Experiments have shown that metformin can inhibit cancer cell growth, but clinical observations have been inconsistent, so we pooled the currently available data to evaluate the impact of metformin on cancer survival and progression. Methods: PubMed, web of science, Embase, and Cochrane databases were searched. Pooled hazard ratios (HRs) were identified using a random-effects model to estimate the strength of the association between metformin and survival and progression in cancer patients. Results: We incorporated 80 articles published from all databases which satisfied the inclusion criterion. It showed that metformin was associated with better overall survival (hazard ratio [HR] = 0. 81; 95% confidence interval [CI]: [0.77–0.85]) and cancer-specific survival (HR = 0.79; 95% CI: [0.73–0.86]), and metformin was associated with progression-free survival (HR = 0.76; 95% CI: [0.66–0.87]). In patients with diabetes mellitus, the HR of overall survival was 0.79(95% CI: [0.75–0.83]), progression-free survival was 0.72(95% CI: [0.60–0.85]), and the cancer-specific survival was 0.76(95% CI: [0.68–0.86]). It was proposed that metformin can improve the prognosis of cancer patients with diabetes mellitus. Conclusion: Based on cohort studies, metformin therapy has potential survival benefits for patients with malignancy, especially with the greatest benefits seen in breast cancer on overall survival, progression-free survival, and cancer-specific survival. And metformin also showed potential benefits in cancer-specific survival in colorectal and prostate cancer.
1 January 2007 in European Journal of Pharmacology
Shan Zha (Hawthorn or Crataegus) is a traditional Chinese medicine (TCM) most commonly used for the treatment of hyperlipidemia. Gastrointestinal cancer is closely correlated with blood lipid levels. This study illustrates the potential anticancer effects of Shan Zha on gastrointestinal tumors based on network pharmacology and molecular docking. Hawthorn's bioactive ingredients and drug targets were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine version 2.0 (TCMIP v2.0), and Herbal Ingredients' Targets Platform (HIT 2.0) databases. Validated disease targets of gastrointestinal cancer were obtained from the Therapeutic Targets Database (TTD) and HIT 2.0 databases. Protein–protein interaction analysis of intersecting genes was performed using the Search Tool for the Retrieval of Interacting Genes (STRING) database. The functions of these genes were further analyzed by performing gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Molecular docking verification was performed using Molecular Operating Environment (MOE) software. Four main bioactive components were identified in Shan Zha. A total of 271 potential drug targets were identified, and 393 gastrointestinal-tumor targets were obtained. Through protein interaction analysis of intersecting targets, the main components of Shan Zha were found to interact more closely with proteins such as tumor protein p53 (TP53), AKT serine/threonine kinase 1 (AKT1), JUN proto-oncogene (JUN), interleukin 6 (IL6), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor A (VEGFA). KEGG pathway enrichment analysis showed a total of 127 pathways, mainly involving pathways in multiple types of cancer, the Phosphatidylinositol 3-kinase-Akt (PI3K-Akt) signaling pathway, and EGFR tyrosine kinase inhibitor resistance. Combined with The Cancer Genome Atlas (TCGA) differential analysis, key targets, including TP53, cyclin D1 (CCND1), EGFR, and VEGFA, were screened. Molecular docking results showed that quercetin and kaempferol had the good binding potential for TP53, CCND1, EGFR, and VEGFA. These findings suggest that Shan Zha exerts its effects on gastrointestinal cancers through a multitarget, multi-component, and a multi-pathway mechanism.
Objective: A Transformer-based multimodal deep learning model was developed to enhance ultrasound imaging diagnosis of PTC and benign nodules. Methods: This study included 491 thyroid nodule patients from two centers, with 406 from the Suzhou Ninth People’s Hospital divided into training ( n = 284) and validation ( n = 122) sets, and 85 from Jiangsu Shengze Hospital as an external test set. The dataset comprised 232 benign nodules and 259 papillary thyroid carcinoma cases. A comparison of 34 deep learning architectures and four traditional models was conducted, leading to the proposal of an Efficientnetv2scbamTrans fusion model. Five ablation experiments assessed module contributions, while SHAP and Grad-CAM were used for interpretability, with energy concentration, peak center distance, and spatial IoU as performance indicators. Results: DenseNet201 excelled on the internal validation set but showed overfitting with an AUC of 0.702 on the external test set. The unimodal imaging baseline had an AUC of 0.782, which improved to 0.811 with clinical features, reducing overfitting risk. Directly fusing radiomics features yielded no improvement, maintaining an AUC of 0.751. The proposed Efficientnetv2scbamTrans model reached an AUC of 0.985 on the internal validation set. More importantly, on the independent external test set (Jiangsu Shengze Hospital), the model achieved an AUC of 0.986 (95% CI: 0.967–1.000), with 96.4% sensitivity and 96.7% specificity. On this external test set, our proposed model significantly outperformed the traditional DLR model by an AUC margin of 0.199 ( p < 0.001). SHAP analysis indicated clinical features altered radiomics decision weights, and Grad-CAM showed an increase in spatial IoU from 0.097 to 0.349, enhancing visual localization. Conclusion: The study developed a multimodal deep learning model using thyroid ultrasound, improving diagnostics with interaction and attention mechanisms via CBAM and Transformer.